Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetirizine for Organ Protection in Severe Burns
NCT06126991Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of cetirizine in burn injury (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Acute Physiology and Chronic Health Evaluation II at Day 7. Started Jan 2024; status: recruiting.
02
Drugs
cetirizine
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT06126991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126991.